Indian Cystic Fibrosis Drugs Market size stood at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period 2019-2028.
Cystic fibrosis (CF) is one of the rare genetic disorder with abnormal movement of sodium and chloride across the gastrointestinal and respiratory tracts. This disorder can be caused because of the development of viscous secretions in the lungs, pancreas, intestines and liver. Patients suffering from this disorder may have difficulty in breathing, mucus formation, fatty stool, and difficulty in the passageway of the pancreas, bile duct, intestine, & salivary gland. It can be diagnosed by the use of sweat test and genetic testing. Physical therapy is most commonly used for the treatment of cystic fibrosis which helps in the reduction of mucus formation and fights against infections of an organ. Above that, treatment of cystic fibrosis invloves the use of drugs such as Pulmozyme, Kalydeco, and others. These drugs can be administered to the patient by different routes such as oral and by inhalation.
Rise in incidence rate of cystic fibrosis in India and increase in medications against cystic fibrosis are the major factors contributing to the market growth. Moreover, rise in R&D investments toward the development of drugs to treat cystic fibrosis propels the cystic fibrosis therapeutics market growth. The high cost of the cystic fibrosis treatment and introduction of generic drugs hinder the growth of the market. Moreover, development of the healthcare industry in the developing economies are expected to create lucrative opportunities in the near future. Above this, rise in prevalence of cystic fibrosis has become a need for newer and advanced therapeutics for its treatment. Hence, this has led to increase in number of pipeline drugs in the market, which lead to provide remunerative opportunities for market expansion during the forecast period.